Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
Submitted by
admin
on October 31, 2018 - 9:45am
Source:
CP Wire
News Tags:
Gilead Sciences
Tango Therapeutics
cancer immunotherapy
Headline:
Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
snippet:
Tango will receive $50 million up front
The company could receive up to $1.7 billion in additional payments
The partnership will focus on building a pipeline of novel immuno-oncology therapies
Do Not Allow Advertisers to Use My Personal information